Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes
Contrary to initial reports, romiplostim treatment of thrombocytopenia does not appear to increase the risk of progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML).Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Health | Leukemia | Myelodysplastic Syndrome | Thrombocytopenia